2020-10-08T18:56:17-05:00 2019-12-31 521754364 E COHEN AND COMPANY CPAS ONE RESEARCH COURT SUITE 400 ROCKVILLE MD 20850 990 2019-01-01 522275294 SARCOMA FOUNDATION OF AMERICA INC SARC 3012538687 9899 MAIN STREET SUITE 204 DAMASCUS MD 20872 BRANDI CLEARY-FELSER EXECUTIVE DIRECTOR 3012538687 2020-09-10 1 KIMBERLY HODOR MAXWELL CPA P00097044 3016913600 2020-08-26 138.88.64.26 2020-09-10 16:56:05 ED P 4C0981783176B4BED85DBF35E17114E39EB077A1 1E4FF37729C9EE3773B63418D2588C03D5E9BD74 2019 2021-01-29 14:40:06Z MARK THORNTON MD PH 9899 MAIN STREET SUITE 204 DAMASCUS MD 20872 4841776 0 X WWW.CURESARCOMA.ORG X 2000 MD WE ADVOCATE FOR SARCOMA PATIENTS BY FUNDING RESEARCH & INCREASING AWARENESS. 12 12 9 482 0 0 2645653 3201729 0 0 207084 118933 89531 -12239 2942268 3308423 1403168 2008432 0 0 507864 531919 46805 62440 224375 690053 568756 2647890 3171547 294378 136876 6491558 7375324 700324 929907 5791234 6445417 X THE MISSION OF THE SARCOMA FOUNDATION OF AMERICA IS TO ADVOCATE FOR SARCOMA PATIENTS BY FUNDING RESEARCH AND BY INCREASING AWARENESS ABOUT THE DISEASE. THE ORGANIZATION RAISES MONEY TO PRIVATELY FUND GRANTS FOR SARCOMA RESEARCHERS AND CONDUCTS EDUCATION AND ADVOCACY EFFORTS ON BEHALF OF SARCOMA PATIENTS. 0 0 2603679 2008432 13772 THE SARCOMA FOUNDATION OF AMERICA (SFA) COORDINATES A NATIONAL RESEARCH GRANT PROGRAM THAT FUNDS TRANSLATIONAL SCIENCE SARCOMA RESEARCH. IN ACCORDANCE WITH THE MISSION OF THE SFA, RESEARCH INVOLVING THE DEVELOPMENT OF NOVEL AGENTS AGAINST SARCOMA, OR RESEARCH THAT COULD POTENTIALLY LEAD TO THE DEVELOPMENT OF NOVEL AGENTS AGAINST SARCOMA, IS SUPPORTED THROUGH THIS FUNDING. THE SFA ENGAGES IN PATIENT EDUCATION PROGRAMS ON THE LATEST DEVELOPMENTS IN SARCOMA RESEARCH AND TREATMENTS. THESE EDUCATION INITIATIVES ARE DESIGNED TO FURTHER STRENGTHEN AND DEEPEN PATIENTS' ABILITY TO PARTICIPATE IN THEIR CARE AND RESEARCH PROJECTS. SFA ALSO CONDUCTS ADVOCACY ACTIVITIES ON BEHALF OF THE SARCOMA COMMUNITY TO ENSURE ADEQUATE FEDERAL CANCER RESEARCH FUNDING LEVELS AND POLICIES THAT POSITIVELY IMPACT SARCOMA PATIENTS. 2603679 1 1 0 1 0 0 0 0 0 1 1 0 0 0 1 1 1 0 0 0 1 1 0 1 1 0 0 1 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 1 11 0 1 9 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 12 12 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 0 0 CA CT FL GA IL KY MA MD MI MN NC NJ NY OR PA SC VA TN UT WV WI MS RI AL AR HI KS NH NM X X THE ORGANIZATION 3012538687 9899 MAIN STREET SUITE 204 DAMASCUS MD 20872 MARK THORNTON MD PHD PRESIDENT 3.00 X X 0 0 0 JOHN SJ BROOKS MD VICE PRESIDENT 1.00 X X 0 0 0 PATRICIA THORNTON TREASURER 3.00 X X 0 0 0 STACEY BREIDINGER SECRETARY 1.00 X X 0 0 0 CHRISTOPHER CONNERY DIRECTOR 1.00 X 0 0 0 MICHAEL LEWIS DIRECTOR 1.00 X 0 0 0 JUSTIN GREEN DIRECTOR 1.00 X 0 0 0 ROBERT GOLDBERG PHD DIRECTOR 1.00 X 0 0 0 AMIRA YUNIS DIRECTOR 1.00 X 0 0 0 THOMAS PEROULAS DIRECTOR 1.00 X 0 0 0 NINA ROKET DIRECTOR 1.00 X 0 0 0 RICHARD RUMSEY CEO 40.00 X 94973 0 7186 BRANDI CLEARY-FELSER EXECUTIVE DIRECTOR 40.00 X 8750 0 175 JENNIFER GOODWIN DIRECTOR 1.00 X 0 0 0 103723 0 7361 0 0 0 0 WORDS DATA AND IMAGES LLC 3190 RIDER TRAIL SOUTH EARTH CITY MO 63045 DIRECT MAIL SERVICE 127494 POWERED BY PROFESSIONALS 1460 BROADWAY 9TH FLOOR NEW YORK NY 10036 CONSULTING, MANAGEMENT, AND FUNDRAISING 104067 2 12321 1951658 1237750 50339 3201729 119761 119761 933234 934062 -828 -828 -828 573280 1951658 599291 -26011 -26011 MISCELLANEOUS REVENUE 900099 11972 11972 CONSULTING FEES 900099 1800 1800 13772 3308423 13772 0 92922 1758432 1758432 250000 250000 111084 77323 22848 10913 355322 226130 92587 36605 6652 4227 1739 686 20111 12828 5261 2022 38750 25218 9640 3892 62440 62440 155665 26453 128136 1076 48279 21226 18169 8884 56700 36899 14106 5695 19462 15918 1201 2343 13378 10667 1413 1298 11971 7790 2979 1202 6379 4151 1587 641 PRINTING AND REPRODUCTI 97829 49839 1497 46493 SOFTWARE 42753 15034 5017 22702 PROMOTIONAL MATERIALS 28168 13577 1141 13450 TELEPHONE AND INTERNET 26333 20520 4141 1672 61839 27447 32031 2361 3171547 2603679 343493 224375 442207 565723 1220327 1112378 153623 160357 44353 53149 164895 68467 22844 96428 4604188 5371823 4016 15466 6491558 7375324 172156 89729 528168 774265 0 65913 700324 929907 X 2810549 4068257 2980685 2377160 5791234 6445417 6491558 7375324 136876 517307 0 X X 0 1 X 1 0 X 1335557 2027706 2093169 2645653 3201729 11303814 363168 249317 304358 552545 573280 2042668 1698725 2277023 2397527 3198198 3775009 13346482 0 0 0 13346482 66500 67767 68574 96149 119761 418751 66500 67767 68574 96149 119761 418751 104497 115788 165101 78258 13772 477416 1869722 2460578 2631202 3372605 3908542 14242649 0.93710 0.93970 0.02940 0.02450 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 631 10672 11303 3160244 3171547 308577 77144 0 0 239320 246645 292231 308577 1086773 1630160 8597 4562 5705 11303 30167 59830 61661 73058 77144 271693 407540 923 1119 335 631 3008 290231 162987 54559 507777 273207 25000 -7976 290231 270676 2531 273207 0.38000 0.00000 0.62000 0 0 78190 460 77730 34262 15564 18698 52443 52443 0 96428 DEFERRED LEASE INCENTIVE 65913 65913 X 3969244 517307 33432 550739 3418505 -110082 -110082 3308423 3315061 33432 110082 143514 3171547 0 3171547 PART X, LINE 2: INCOME TAXES NO PROVISION HAS BEEN MADE FOR INCOME TAXES, SINCE THE ORGANIZATION HAS BEEN DETERMINED TO BE EXEMPT FROM INCOME TAX PURSUANT TO INTERNAL REVENUE CODE SECTION 501(C)(3). THERE WAS NO NET UNRELATED BUSINESS TAXABLE INCOME DURING THE YEAR. THE ORGANIZATION ADOPTED THE FINANCIAL ACCOUNTING STANDARDS BOARD FASB ASC 740-10, INCOME TAXES, WHICH REQUIRES AN ASSESSMENT OF UNCERTAINTY IN INCOME TAXES AND CERTAIN FINANCIAL STATEMENT DISCLOSURES RELATING TO UNRECOGNIZED TAX BENEFITS. FOR THE YEAR ENDED DECEMBER 31, 2019, THE ORGANIZATION HAS DETERMINED THAT NO MATERIAL UNCERTAIN TAX POSITIONS EXIST REQUIRING EITHER RECOGNITION OR DISCLOSURE IN THE FINANCIAL STATEMENTS. NO RETURNS ARE CURRENTLY UNDER EXAMINATION. PART XI, LINE 4B - OTHER ADJUSTMENTS: FUNDRAISING EXPENSES INCLUDED ON 990 LINE 8B WHICH WERE NOT A DIRECT BENEFI TO THE DONOR, INCLUDED AS FUNDRAISING EXPENSE FOR AUDIT PURPOSES. PART XII, LINE 2D - OTHER ADJUSTMENTS: FUNDRAISING EXPENSES INCLUDED ON 990 LINE 8B WHICH WERE NOT A DIRECT BENEFI TO THE DONOR, INCLUDED AS FUNDRAISING EXPENSE FOR AUDIT PURPOSES. PART XI LINE 4B, AND PART XII LINE 2D FUNDRAISING EXPENSES INCLUDED ON 990 LINE 8B WHICH WERE NOT A DIRECT BENEFIT TO THE DONOR WERE INCLUDED AS FUNDRAISING EXPENSE FOR AUDIT PURPOSES. 1 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 PROGRAM SERVICES CANCER RESEARCH 200000 NORTH AMERICA 0 0 PROGRAM SERVICES CANCER RESEARCH 50000 0 0 0 0 0 0 250000 0 250000 EUROPE CANCER RESEARCH 50000 WIRE FMV EUROPE (INCLUDING ICELAND & GREENLAND) CANCER RESEARCH 50000 WIRE FMV NORTH AMERICA CANCER RESEARCH 50000 WIRE FMV EUROPE (INCLUDING ICELAND & GREENLAND) CANCER RESEARCH 50000 WIRE FMV EUROPE (INCLUDING ICELAND & GREENLAND) CANCER RESEARCH 50000 WIRE FMV 0 5 0 0 0 0 0 0 PART I, LINE 2: GRANTEES ARE REQUIRED TO PROVIDE FINAL SCIENTIFIC REPORT AND FINAL FINANCIAL REPORT AFTER THE CONCLUSION OF THE ONE-YEAR GRANT PERIOD. PART III ACCOUNTING METHOD: X X X 1 POWERED BY PROFESSIONALS INC 1460 BROADWAY 9TH FLOOR NEW YORK NY 10036 CONSULTING, MANAGEMENT, AND FUNDRAISING SERVICES FOR GALA 0 698982 62440 698982 698982 62440 698982 CA CT FL GA IL MA MD MI MN NC NJ NY OR VA WI MS RI TN UT WV AL PA SC KY CO OH WA MO AK AR DC HI KS ME NV NH NM OK GALA 748982 702150 46832 109287 1600 9000 38850 CHICAGO (RTCS 2019) 242278 196804 45474 2072 1805 300 23143 18 1533678 1052704 480974 0 17761 46590 33251 7707 307925 2524938 1951658 573280 17761 157949 36656 17007 369918 599291 -26011 SCHEDULE G, PART I, LINE 2B, COLUMN (V) CURRENT CONTRACT- $6,500 PER MONTH. CURRENT YEAR PAYMENTS WERE $104,067 PORTION RELATED TO EVENT PROGRAM: $26,017, MANAGEMENT: $15,610, PORTION RELATED TO FRP: $62,440. 1 CEDARS-SINAI MEDICAL CENTER 951644600 501C3 50000 CANCER RESEARCH SITEMAN CANCER CENTER 430653611 501C3 82288 CANCER RESEARCH UNIVERSITY OF PITTSBURGH 250965591 501C3 137554 CANCER RESEARCH FOX CHASE CANCER CENTER 232003072 501C3 22975 0 CANCER RESEARCH CLEVELAND CLINIC 340714585 501C3 107490 0 CANCER RESEARCH FRED HUTCHINSON CANCER RESEARCH CENTER 237156071 501C3 50000 0 CANCER RESEARCH VCU MASSEY CANCER CENETR 546053660 501C3 9020 0 CANCER RESEARCH MEMORIAL SLOAN-KETTERING CANCER CENTER 131924236 501C3 300000 0 CANCER RESEARCH STANFORD UNIVERSITY 941156365 501C3 125000 0 CANCER RESEARCH CONQUER CANCER FOUNDATION 311667995 501C3 287500 0 CANCER RESEARCH MEDICAL COLLEGE OF WISCONSIN 390806261 501C3 55290 0 CANCER RESEARCH LURIE CANCER CENTER 362167817 501C3 107480 0 CANCER RESEARCH VANDERBILT-INGRAM CANCER CENTER 352528741 501C3 16880 0 CANCER RESEARCH UNIVERSITY OF KANSAS HEALTH SYSTEM 481202402 501C3 29685 0 CANCER RESEARCH CU FOUNDATION 521749045 501C3 27270 0 CANCER RESEARCH CINCINNATI CHOLDREN'S HOSPITAL MEDICAL CENTER 310839936 501C3 50000 CANCER RESEARCH MASSACHUSETTS GENERAL HOSPITAL 042697983 501C3 50000 CANCER REASEARCH MD ANDERSON CANCER CENTER 746001118 501C3 50000 CANCER RESEARCH SARC 861087705 501C3 100000 CANCER RESEARCH TUFTS UNIVERSITY 042103634 501C3 50000 CANCER RESEARCH UNIVERSITY OF WASHINGTON 916001537 501C3 50000 CANCER RESEARCH 21 PART I, LINE 2: APPLICANTS FOR SFA GRANTS MUST SUBMIT AN APPLICATION OUTLINING THEIR PROPOSED RESEARCH PROJECT ALONG WITH A DETAILED BUDGET THAT DEMONSTRATES HOW THE AWARD MONEY IS TO BE USED. APPLICANTS ARE MADE AWARE THAT A REQUIREMENT OF THE ACCEPTANCE OF GRANT MONEY IS THAT A FINAL REPORT WILL BE SUBMITTED TO SFA AT THE END OF THE ONE-YEAR GRANT PERIOD. THE FINAL REPORT AND BUDGET IS DUE TO SFA BY JULY 31ST OF THE YEAR AFTER THE AWARD IS MADE. FINAL REPORTS ARE TO CONTAIN INFORMATION ON HOW THE RESEARCH PROGRESSES AND IT MUST BE SIGNED BY BOTH THE PRIMARY INVESTIGATOR AS WELL AS THEIR DEPARTMENT CHAIR. X 1 600 FMV X 23485 FMV X 1 7768 FMV X VACATION PACKAGE 3 8100 X TICKETS 7 7836 FMV X PROMOTIONAL GOODS 2 2550 FMV 0 0 1 PART I, LINE 32B: POWERED BY PROFESSIONAL SOLICITS AND PROCESSES SILENT AUCTION OF ANNUAL GALA. FORM 990, PART VI, SECTION A, LINE 2 MARK THORNTON, PRESIDENT, AND PATRICIA THORNTON, TREASURER, ARE HUSBAND AND WIFE. FORM 990, PART VI, SECTION B, LINE 11B THE DIRECTOR OF FINANCE AND ADMINISTRATION, TREASURER AND EXECUTIVE DIRECTOR REVIEW THE 990 BASED ON THE FINANCIAL RECORDS, POLICIES AND PROGRAMS OF THE ORGANIZATION. FORM 990, PART VI, SECTION B, LINE 12C AT LEAST ONCE A YEAR, OFFICERS ACTING ON BEHALF OF THE SARCOMA FOUNDATION OF AMERICA, INC., SHALL EXECUTE AND SUBMIT A STATEMENT TO THE PRESIDENT DISCLOSING ALL MATERIAL FACTS CONCERNING ANY ACTUAL OR POTENTIAL CONFLICT OF INTEREST OR CONFIRMING THAT THERE ARE NO SUCH CONFLICTS TO BE DISCLOSED. FORM 990, PART VI, SECTION B, LINE 15A THE BOARD OF DIRECTORS HAS AN APPOINTED COMPENSATION COMMITTEE THAT REVIEWS AND APPROVES THE SALARY OF THE EXECUTIVE DIRECTOR ON AN ANNUAL BASIS USING CURRENT ECONOMIC COMPARATIVE DATA. FORM 990, PART VI, SECTION C, LINE 19 GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY ARE AVAILABLE UPON REQUEST. FINANCIAL STATEMENTS ARE AVAILABLE ON THE WEBSITE AS WELL AS UPON REQUEST. FORM 990, PART XII, LINE 2C THE ORGANIZATION HAS NOT CHANGED EITHER ITS OVERSIGHT PROCESS OR SELECTION PROCESS DURING THE TAX YEAR.